Original document(206 pages)  中文版
    The present invention relates to novel antibodies, particularly antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to the type III deletion mutant, EGFRvIII. The invention also relates to human monoclonal antibodies directed against deletion mutants of epidermal growth factor receptor and particularly to EGFRvIII. Diagnostic and therapeutic formulations of such antibodies, and immunoconjugates thereof, are also provided.
Application Number
申请号		 200480018185 Application Date
申请日		 2004.06.25
Title 名称 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
Publication Number
公开号		 1930187 Publication Date
公开日		 2007.03.14
Approval Pub. Date Granted Pub. Date
International Classification 分类号 C07K16/28;C07K16/42;C07K14/71;C12P21/08;A61K39/44;A61K39/395;C07H21/04;C12N5/12;G01N33/53;G01N33/552;G01N33/577
Applicant(s) Name
申请人		 Abgenix Inc.
Address 地址
Inventor(s) Name 发明人
Attorney & Agent 代理人 wangyuan fang liuguo wei
More information 更  多  信  息


 Related patents information
Promoted portability of effective telephone-number
Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
Google
Note:All patent data come from State Intellectual Property Office of the People's Republic of China. If there were discrepancies between here and the State Intellectual Property office, the later is more accurate. The patent data is only for public exchange and learning purposes. We are not responsible for the adverse consequences with unverified use of the data.